Share |

Verisante Technology, Inc. was incorporated in March 2006 to bring together a team of high-level academic researchers, medical device industry experts, and corporate finance professionals to execute a targeted product strategy focused on the early detection of cancer.

The Company's initial focus is on the commercialization of Verisante Aura™ a device for the early detection of all forms of skin cancer, including basal cell carcinoma, squamous cell carcinoma and melonoma.

Verisante has the exclusive world wide rights to a technology developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine for in vivo, real-time, non-invasive skin lesion measurements on which Verisante Aura™ is based.

The Company's platform technology is also fully extensible to early detection systems for other types of cancer, including lung, gastro-intestinal, colorectal and cervical cancers. The Verisante Core™ series of devices will focus on these types of cancers

  Back to top